KRAS and neoplasm: The analysis' results showed that the prognostic value of exon 2/3 K-Ras mutations is retained after correction for other well-known prognostic factors (age at diagnosis, tumor tissue used for molecular analysis, reference center, number of metastatic sites and first-line chemotherapy) and confirm the robustness of the mutation rate as an effective predictor of PFS and OS.